Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics reported a cash position of $596 million as of March 31, 2026, maintaining a strong financial position. The company's R&D expenses increased by 24% to $70 million in Q1 2026, primarily due to accelerating clinical trial activity and a $5 million milestone payment to Impact Therapeutics for EIK1003. G&A expenses rose by 17% to $17.3 million, driven by higher depreciation and professional fees following the occupation of Eikon's Millbrae headquarters.
Key figures
- Eps
- 0
- Eps Beat
- 0
- Revenue
- 0
- Revenue Yoy
- 0
- Net loss
- 83000000
- Net loss yoy
- 11.4%
- Cash position
- 596000000
- G and a expenses
- 17300000
- R and d expenses
- 70000000
- Milestone payment
- 5000000
- G and a expenses yoy
- 17%
- R and d expenses yoy
- 24%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.